JN Biosciences LLC

May 28, 2020

A phase 2 clinical study with a humanized anti-TIGIT IgG1 monoclonal antibody (AB154, domvanalimab) sponsored by Arcus Biosciences for treatment of non-small cell lung cancer was initiated (NCT04262856).  The title of the study is "Study to Evaluate Monotherapy and Combination Immunotherapies in Participants With PD-L1 Positive Non-small Cell Lung Cancer (ARC-7)."

January 21, 2020

A U.S. Patent entitled "Antibodies to TIGIT" (US10537633), on which JN Biosciences' J Yun Tso and Naoya Tsurushita are inventors, was issued.